Cargo Therapeutics Executive Compensation (FY24)
CRGX · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024 ◇ Gina Chapman |
Velarion Member: every covered company in one industry, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The Cargo Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Data as of October 19, 2026Latest filing (DEF 14A): April 29, 2025
2 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Member, one year
112 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Gina Chapman: $4,992,389 → $9,300,120 (86.3% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Cargo Therapeutics' chief executive and what were they paid?
Gina Chapman, President and Chief Executive Officer, received $9,300,120 in total compensation for fiscal 2024. Compared with the $4,992,389 reported for fiscal 2023, Chapman's total was 86.3% higher.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Gina Chapman President and Chief Executive Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Gina Chapman President and Chief Executive Officer | ◇ | ◇ | — | ◇ | ◇ | — | — | ◇ |
Anup Radhakrishnan Chief Financial Officer and Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Ginna Laport Chief Medical Officer | ◇ | ◇ | — | ◇ | ◇ | — | — | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Gina Chapman President and Chief Executive Officer | ◇ | ◇ | — | ◇ | ◇ | — | — | ◇ |
Anup Radhakrishnan Chief Financial Officer and Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Ginna Laport Chief Medical Officer | ◇ | ◇ | — | ◇ | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Anup Radhakrishnan | OPTION | ◇ | — | — | ◇ | — | — | — |
| Anup Radhakrishnan | OPTION | ◇ | — | — | ◇ | — | — | — |
| Gina Chapman | RSA | ◇ | — | — | ◇ | — | — | — |
| Gina Chapman | OPTION | ◇ | — | — | ◇ | — | — | — |
| Gina Chapman | OPTION | ◇ | — | — | ◇ | — | — | — |
| Ginna Laport | OPTION | ◇ | — | — | ◇ | — | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Anup Radhakrishnan | Option | ◇ | — | ◇ | 10/6/2032 |
| Option | ◇ | — | ◇ | 11/8/2033 | |
| Option | ◇ | — | ◇ | 4/20/2033 | |
| Option | ◇ | — | ◇ | 8/29/2033 | |
| Option | ◇ | — | ◇ | 4/20/2033 | |
| Option | ◇ | — | ◇ | 4/20/2033 | |
| Option | ◇ | — | ◇ | 2/28/2034 | |
| Option | ◇ | — | ◇ | 11/11/2034 | |
| Gina Chapman | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 4/20/2033 | |
| Option | ◇ | — | ◇ | 4/20/2033 | |
| Option | ◇ | — | ◇ | 4/20/2033 | |
| Option | ◇ | — | ◇ | 2/28/2034 | |
| Ginna Laport | Option | ◇ | — | ◇ | 10/10/2033 |
| Option | ◇ | — | ◇ | 2/28/2034 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Anup Radhakrishnan
Chief Financial Officer and Chief Operating Officer · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
Gina Chapman
President and Chief Executive Officer · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
Ginna Laport
Chief Medical Officer · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Kapil Dhingra | ◇ | — | ◇ | — | — | — | ◇ |
Jane Pritchett Henderson | ◇ | — | ◇ | — | — | — | ◇ |
John Orwin Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Krishnan Viswanadhan | ◇ | — | ◇ | — | — | — | ◇ |
David C. Lubner | ◇ | — | ◇ | — | — | — | ◇ |
Reid Huber | ◇ | — | ◇ | — | — | — | ◇ |
Abraham Bassan | ◇ | — | ◇ | — | — | — | ◇ |
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Gina Chapman (President and Chief Executive Officer), FY2024 total compensation $9,300,120 (base salary $630,800) [exec_comp, SEC accession 0001193125-25-103786, filed 2025-04-29]What this page does not include
Everything above is a fact Cargo Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
112 figures on this page, cited to the filing that reported them.
112 cited to the filing
Documents cited
- 0001193125-25-1037862024 Summary Compensation Table · DIRECTOR COMPENSATION · Director compensation table · EXECUTIVE COMPENSATION · and 2 more sections
- 0001193125-24-110173
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Cargo Therapeutics executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/CRGX (accessed 2026).
Short form: data: Velarion
The Cargo Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
2 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Cargo Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}